The U.S. health regulator extended the review of Bristol Myers Squibb’s oral heart disease drug candidate mavacamten, which the company acquired in its $13 billion buyout of MyoKardia during 2020.
BridgeBio Pharma secured credit assistance worth as much as $750 million to move forward with the company’s research and development efforts for the treatment of cancers and genetic diseases.
Gilead Sciences exercised options to three of Arcus Biosciences’ programs, and the two companies also added a research collaboration deal.
Sanofi is investing in French American startup Owkin to support drug discovery and development initiatives in four types of cancer.
AstraZeneca on Thursday cemented the company’s lead in bringing a preventative Covid-19 shot to market, saying its antibody cocktail offered 83 percent protection over six months, another possible weapon in the fight against the pandemic.
Shares of Dicerna Pharmaceuticals exploded today after Novo Nordisk announced plans to acquire the Lexington, Mass.-based , a company developing RNAi therapeutics, company for $3.3 billion.
Johnson & Johnson expects to file for approval of 14 new drugs by 2025, and projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of the company’s pharmaceuticals unit on November 18.
Moderna Inc. said on November 17 the company had applied with the U.S. Food and Drug Administration for authorization of the Covid-19 booster vaccine for all adults aged 18 and older.
Iterum Therapeutics will head back into the clinic to meet regulatory requirements to refile a New Drug Application for oral sulopenem, which has been developed to treat uncomplicated urinary tract infections.
Pfizer Inc. said on November 16 the company is seeking U.S. authorization of the experimental antiviral Covid-19 pill Paxlovid that cut the chance of hospitalization or death for adults at risk of severe disease by 89 percent in a clinical trial.
